Stock Groups

Merck’s COVID-19 drug to be reviewed by U.S. FDA advisers- Bloomberg News By Reuters

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO: FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid

(Reuters) – The U.S. Food and Drug Administration will send drugmaker Merck & Co’s COVID-19 antiviral drug, molnupiravir, to a panel of its outside advisers for a review, Bloomberg News reported on Thursday, citing a person familiar with the plans.

According to the report, an advisory committee will review safety concerns raised by experts before FDA decides on drug authorization.

Disclaimer Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media does not accept any liability for trade losses or other consequences arising from the use of these data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.



[ad_2]